Mammoth Biosciences develops CRISPR-Cas-based gene editing therapeutics and diagnostics to enable precise in vivo applications for serious diseases and molecular detection. Their technology addresses the challenges of gene delivery and expands testing capabilities, providing permanent solutions for unmet medical needs.
Funding
$374.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
+5Founders
Product
Problem
Current gene editing technologies face challenges in efficient and safe in vivo delivery, limiting their therapeutic potential for many diseases. Existing diagnostic methods also lack the speed and versatility needed for rapid molecular detection in diverse settings.
Solution
Mammoth Biosciences is developing CRISPR-Cas-based therapeutics utilizing novel CRISPR enzymes and editing strategies to overcome in vivo delivery challenges and enable precision gene editing. The company's protein discovery and engineering platform focuses on discovering and engineering novel CRISPR-Cas systems and editing modalities to overcome delivery limitations. Mammoth Biosciences is also creating a CRISPR-based detection platform for molecular diagnostics, enabling limitless testing possibilities.
Target Audience
The primary target audience includes patients with serious diseases, researchers in gene editing and molecular diagnostics, and healthcare providers seeking advanced therapeutic and diagnostic solutions.
Features
- Novel CRISPR-Cas enzymes for in vivo gene editing
- Protein discovery and engineering platform to overcome delivery challenges
- CRISPR-based detection platform for molecular diagnostics
- Focus on developing permanent cures through precision editing
- Development of novel editing modalities